The monthly cost of Rinvoq (upadacitinib) can vary significantly, influenced by insurance coverage, dosage, and whether it is purchased through a pharmacy or a patient assistance program. Without insurance, a one-month supply can range from approximately \$6,000 to over \$8,000 [1].
What factors influence Rinvoq's price?
Several elements contribute to the cost of Rinvoq. These include the specific formulation (e.g., extended-release tablets), the prescribed dosage, and the quantity dispensed. Pharmacy pricing also differs, and the presence of co-pay assistance programs can substantially lower out-of-pocket expenses for eligible patients [1].
How can I get financial assistance for Rinvoq?
AbbVie, the manufacturer of Rinvoq, offers patient assistance programs. These programs can provide co-pay cards for commercially insured patients, potentially reducing their monthly out-of-pocket costs to as low as \$5 per month [1]. For uninsured or underinsured patients who meet certain income criteria, the AbbVie Patient Assistance Foundation may offer free medication [1].
When does Rinvoq's patent expire?
Information regarding the specific patent expiration dates for Rinvoq is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods. These dates are crucial for understanding when generic or biosimilar versions might become available [2].
What are the approved uses for Rinvoq?
Rinvoq is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several autoimmune conditions. These include moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have had an inadequate response or intolerance to one or more TNF blockers [1].
How does Rinvoq work?
Rinvoq is a Janus kinase (JAK) inhibitor. It works by selectively blocking specific JAK enzymes, which are involved in the signaling pathways that trigger inflammation in the body [1]. By inhibiting these pathways, Rinvoq helps to reduce inflammation associated with various autoimmune diseases.
What are the potential side effects of Rinvoq?
Like other JAK inhibitors, Rinvoq carries a boxed warning concerning increased risks of serious infections, mortality, major adverse cardiovascular events, thrombosis, and malignancies [1]. Common side effects can include upper respiratory tract infections, acne, fever, increased blood cholesterol levels, and rash [1]. Patients should discuss all potential risks with their healthcare provider.
How does Rinvoq compare to other treatments for autoimmune diseases?
Rinvoq offers an alternative treatment option for individuals with certain autoimmune conditions who have not responded well to other therapies. Its mechanism as a JAK inhibitor distinguishes it from other drug classes like TNF blockers. The choice of treatment depends on the specific condition, disease severity, patient history, and individual risk factors [1].
What is the difference between Rinvoq and other JAK inhibitors?
Rinvoq (upadacitinib) is a selective JAK1 inhibitor. Other JAK inhibitors may target different JAK enzyme combinations (e.g., JAK1/JAK2, JAK1/JAK2/JAK3, or pan-JAK inhibitors), which can influence their efficacy and safety profiles. The selectivity of Rinvoq for JAK1 is intended to help differentiate its therapeutic effects and side effect profile from broader-spectrum JAK inhibitors [1].
Who makes Rinvoq?
Rinvoq is manufactured by AbbVie [1].
What is the future outlook for Rinvoq pricing and availability?
The future cost and availability of Rinvoq will be influenced by patent expirations and the potential introduction of generic or biosimilar competitors. Market analysis and patent data from sources such as DrugPatentWatch.com provide insights into these timelines [2]. Patient assistance programs are also a key factor in current affordability.
Sources
1. AbbVie Inc. Rinvoq. https://www.rinvoq.com/
2. DrugPatentWatch.com. https://drugpatentwatch.com/